BriaCell Therapeutics Corp.

BCTX Nasdaq SEC CIK 1610820
Follow BriaCell Therapeutics Corp. Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2026 USD · US GAAP
Net income −$12.3M −52.3% vs same quarter last year
EPS, diluted -
Operating cash flow −$6M +26.7% vs same quarter last year
Operating income −$12.6M −47.1% vs same quarter last year
Net income by quarter
−$5.8M
−$6.3M
−$6.1M
−$8.1M
−$8.2M
−$7.2M
−$7.2M
−$12.3M
Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 Q4 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$40M−$30M−$20M−$10M$0FY20FY21FY22FY23FY24FY25FY26
Show the numbers
YearNet income
FY26−$34.9M
FY25−$26.3M
FY24−$4.8M
FY23−$20.3M
FY22−$26.8M
FY21−$13.8M
FY20-